Many drugs are metabolized by highly polymorphic cytochrome P450 (CYP) enzymes. Among these enzymes, members of the CYP2 family coded by the CYP2D6, CYP2C9 and CYP2C19 genes are best amenable to the precise prediction of an individual's innate capacity to metabolize drugs by DNA typing of inherited null and deficient alleles. We determined the frequency of these alleles and the prevalence of their carriers in a New England, USA, tertiary care center to assess underlying population genetic features for the practice of personalized medicine. We determined that 54, 25 and 27% are carriers of at least one deficient or null allele for the CYP2D6, CYP2C9 and CYP2C19 genes, respectively. Furthermore, 6% of individuals are carriers of two null alleles for CYP2D6 and are predicted to have no biochemical activity for this isoenzyme. These results support the implementation of DNA typing of CYP2 genes to diagnose adverse drug reactions and to prevent a substantial number of patients being prescribed drugs they cannot adequately metabolize.
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Many drugs are metabolized by the highly polymorphic cytochrome P450 (CYP) enzymes. Determining each patient's innate drug metabolism capacity could reduce adverse drug reactions (ADRs). Over 100,000 ADRs occur annually in the USA, and 17% of such patients require hospitalization at an estimated cost of US$182 billion [1] . More than 57 CYP genes are known [2] . The gene families CYP1, CYP2 and CYP3 are responsible for the oxidative metabolism of over 75% of all ingested drugs [3] . The principal CYP enzymes whose function can be predicted from genetically inherited alleles belong to the CYP2 family and are coded by genes CYP2D6, CYP2C9 and CYP2C19, which are predominantly expressed in the liver. These isoenzymes are highly variable in drug metabolizing activity in human populations. The heterogeneous drug metabolizing individual characteristics (phenotypes) are predictable for each person from inherited DNA variant sequences (alleles) in the respective CYP2 genes.
The structural variances in CYP2 isoenzymes are the basis of the classical phenotypes conventionally known as ultrarapid (UM), extensive (EM), intermediate (IM) and poor metabolizers (PM) and are determined empirically by pharmacological probes [4] . The UM status conveys accelerated and supra-functional drug metabolism, which can prevent a drug at standard dosage from achieving therapeutic effect. The EM status represents normal function and drug metabolism capacity. The IM and PM status indicates progressively impaired metabolic capacity, with resultant higher than average serum drug levels. The opposite clinical effects are observed for each phenotypic category with pro-drugs, which require hepatic metabolism to derive active metabolites. It is now possible to determine by DNA typing whether a patient is a carrier of deficient or null alleles in CYP2D6, CYP2C9, and CYP2C19 genes, and to use genetic terminology to describe a patient's innate metabolic capacity. DNA typing could become a powerful tool for the diagnosis and prevention of ADRs and the optimization of therapeutic dosing [5, 6] .
The primary goal of this study was to determine, in parallel, the frequency of CYP2D6, CYP2C9 and CYP2C19 deficient and null alleles in a clinical population of patients at an urban tertiary care center in the northeast of the USA. This paper summarizes results from 121 patients being treated for dyslipidemias at such a facility, and utilizes a novel assay system capable of DNA typing several alleles in each of the three genes. A secondary aim was to determine if the diversity and frequency of the alleles identified in the study support the implementation of routine DNA typing to ascertain a patient's innate drug metabolizing capacity.
Materials & methods

Patient enrollment
As part of a study on dyslipidemias, patients treated with statins at Hartford Hospital (CT, USA) for at least 1 month were recruited and provided informed written consent as approved by the Institutional Review Board [7] . All patients were adults and unrelated. CYP DNA typing data was obtained on 121 patients. On a per gene basis, we obtained DNA typing data on these patients for 95, 107, and 121 individuals for the CYP2D6, CYP2C9 and CYP2C19 genes, respectively. The ages of patients ranged between 40 and 80; 63% were male and 37% were female. The ethnicities of the surveyed population were obtained from each participant's self-report at recruitment. The ethnic composition of the survey thus obtained was 87% Caucasian, 3% African-American, 9% Hispanic and 1% Asian.
Laboratory analysis
Samples were collected into tubes containing either ethylendiamine tetraacetic acid (EDTA) or citrate and were extracted from lymphocytes using the Puregene™ Gentra (MN, USA) DNA isolation kit. DNA typing was performed at the Genomas Laboratory of Personalized Health (LPH) at Hartford Hospital. LPH is a high-complexity clinical DNA testing center licensed by the Connecticut Department of Public Health (CL-0644) and certified by the Centers for Medicare and Medicaid Services (ID number 07D1036625) under Clinical Laboratory Improvement Amendments (CLIA).
The Tag-It™ Mutation Detection assays (Tm BioScience, Toronto, Canada) were utilized for DNA typing of 14, 5 and 7 alleles in CYP2D6, CYP2C9 and CYP2C19 genes, respectively (Tables 1-3 ) [8] . The wild-type allele, *1, is determined by the absence of the alleles typed in the assays. These assays employed polymerase chain reaction (PCR) to selectively amplify the desired CYP2 genes without co-amplifying pseudogenes or other closely related sequences. In addition, the kit employs a PCR strategy to amplify fragments characteristic of unique genomic rearrangements, in order to detect the presence of the deletion and duplication alleles in CYP2D6. The kits use multiplexed allele specific primer extension (ASPE) to identify small nucleotide variations, including single base changes and deletions of one or three bases. In brief, a PCRderived target DNA is reacted with two universally-tagged allele-specific primers whose 3' ends define the alleles used for each variation tested. A thermophilic DNA polymerase was used for primer extension and biotin-deoxycytidine triphosphate (dCTP) label incorporation. As the two tagged allele-specific primers overlap the single nucleotide polymorphism (SNP) site in the target DNA, only the correctly hybridized primers were extended to generate labeled products. Single tagged ASPE primers were used to detect the presence of unique PCR fragments generated for the deletion and duplication gene rearrangements. Following ASPE, tagged, extended products labeled with biotin were captured by their tag complements (anti-tags), which had been chemically coupled to spectrally addressable polystyrene microspheres. A fluorescent reporter molecule (streptavidin-phycoerythrin) was used to detect incorporated biotin. The fluorescent reporter signals generated for each bead population was measured on the Luminex xMAP™ system. (Luminex Corporation, TX, USA).
Conventions for naming the alleles according to the Human CYP Allele Nomenclature Committee have been followed in this research [101] . Accordingly, all alleles contain nucleotide changes that have been shown to affect transcription, splicing, translation, posttranscriptional or posttranslational modifications, or result in at least one amino acid change. Tables 1-3 list the alleles of most clinical significance for each gene based on their molecular nature. We describe the alleles as null, deficient, or normal based on well-defined molecular properties of the altered gene. Null alleles lack any enzymatic activity as the altered gene does not produce a functional protein. Such null alleles result from gene deletions, false stop codons, frameshift and missense mutations, and splicing defects. Deficient alleles have subfunctional enzymatic activity due to DNA base substitutions resulting in amino acid changes in the protein, and may be expected to manifest subfunctional enzymatic activity with regard to at least some drug substrates. The normal allele refers to status as genetic wild type, inferred only by the absence of the deficient or null alleles listed for each gene. The duplication allele for CYP2D6 refers to a tandem configuration of two or more gene copies in the same chromosome, which may result in supra-functional enzymatic activity depending on the allele replicated. Table 1 presents the allele frequencies for the CYP2D6 gene. Among the null alleles, *4, a splicing defect, is the most common, found at a frequency of 16%. Other null alleles observed were *3 at 1.5% and *12 at 1% frequency. Of note is the 3% frequency of the *5 allele, the gene deletion. Of the deficient alleles, the most common in our sample was allele *17, which was observed at 5% frequency. Other deficient alleles were *10 High carrier prevalence of deficient and null alleles of CYP2 genes -RESEARCH REPORT and *9, each at 3% frequency. Significantly, we also observed the duplication allele at a frequency of 1.5%. Allele *2 is very common at a frequency of 32%, but is considered a functional allele. The *2 frequency, if added in full to the wild-type frequency of 34%, provides an upper estimate of normal allele frequency of 66% for CYP2D6. However, this is likely to be an overestimate, as any subfunctional variants related to the *2 allele may render it compromised in enzymatic activity. Table 2 presents the allele frequencies for the CYP2C9 gene. The commonly observed alleles for this gene are all deficient. The frequency of the most common, allele *2, is 9%. Alleles *3 and *4 were observed at frequencies of 4 and 1%, respectively. Table 3 presents the allele frequencies for the CYP2C19 gene. The commonly observed alleles for this gene are all null. The frequency of allele *2, the most common allele is 13%; and of alleles *4 and *8, a total of 1%. Figures 1-3 represent the carrier prevalence of null and deficient alleles in the population. Noncarriers have two copies of normal alleles. Carriers have one copy of a deficient or null allele and one copy of a normal allele. Double carriers may have two copies of deficient alleles or one copy each of a deficient and a null allele, or two copies of null alleles. Individuals who are carriers of a gene duplication allele and a normal allele are classified as duplication carriers. Figure 1 depicts the carrier prevalence for CYP2D6. The prevalence of noncarrier individuals was 46% of the total patient sample. More than 50% of the population carried at least one subfunctional allele: 40% of the population was a single carrier and 13% was a double carrier. Within the double carrier subgroup, most had at least one null allele. The prevalence of carriers of two null alleles was 6%. One percent of the population carried the duplication allele for the CYP2D6 gene. Figure 2 depicts the carrier prevalence for CYP2C9. The prevalence of double and single carriers was 3 and 22%, respectively, and that of noncarriers, 75%. Among single carriers, the prevalence was 13% for *2 single carriers, 7% for *3 single carriers and 2% for *4 single carriers. Among double carriers, the prevalence was 2% for *2, *2 double carriers and 1% for *2, *3 double carriers (data not shown). Figure 3 depicts the carrier prevalence for CYP2C19. The prevalence of carriers was 27%, and that of noncarriers is 73%. There were no double carriers in this sample. 
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Discussion
The present study examined DNA obtained from patients in a northeast USA urban tertiary care center (Hartford Hospital). We found a remarkably high frequency and carrier prevalence of DNA alleles for the CYP2D6, CYP2C9 and CYP2C19 genes, a family of genes known to affect drug metabolism and drug levels. These patients had been treated with statins for at least 1 month. Statins are metabolized primarily by the CYP3 family [9] . Hence, it is unlikely that these patients were selected for variants in the CYP2 family, although this possibility cannot be excluded. We identified CYP2D6 alleles which revealed remarkable diversity consistent with an urban population of heterogeneous ethno-geographic ancestry. We observed allele *4, found commonly in Caucasian populations, allele *17, found predominantly in individuals of African ancestry, allele *10, found predominantly in Far East populations, and the gene duplication allele, traceable to Northern Africa and the Near East [10, 11] . Our results point to the heterogeneity of patients in urban medical centers in general, and to the recognition of DNA typing as a tool in dealing with this diversity.
The resolution provided by DNA typing provides practical clinical significance to the various historical drug metabolizer phenotypes. The classical pharmacokinetic 'poor' and 'intermediate' metabolizer phenotypes, widely reported at 10 and 40% of the population, respectively, for CYP2D6, can now be resolved into categories defined by their carrier status. We prefer to classify patients as carriers of two null alleles, carriers of one null and one deficient allele, carriers of two deficient alleles, and carriers of a single deficient or null allele. In our survey, 6% of subjects had no CYP2D6 enzymatic activity because they are carriers of two null alleles for the gene. Additionally, 7% of subjects can be expected to be highly compromised for CYP2D6 activity because they carry one copy each of a null and deficient allele, or two copies of a deficient allele. The extensive metabolizer phenotype can now be assessed from individuals who are not carriers of deficient or null alleles, 46% of the population in our survey. High carrier prevalence of deficient and null alleles of CYP2 genes -RESEARCH REPORT For CYP2C9, it is possible to differentiate between single carriers of alleles *2 or *3, who represent 22% of the population, and double carriers, who represent 3%. Thus, CYP2C9 metabolizer phenotypes can also be resolved at high resolution with DNA typing. [12] The CYP2C19 gene is the least polymorphic of the CYP2 genes examined. The prevalence of carriers is 27%. We did not observe any double carriers of CYP2C19 null alleles, expected at a prevalence of approximately 2% given the observed null allele frequency. However, this deviation is not unexpected given our sample size. Significantly, the observed CYP2C19 alleles are null, which render all carriers compromised in their biochemical activity for the respective isoenzyme.
One limitation of the resolution of this study is that the universe of alleles for the CYP2 genes continues to expand with discovery efforts in various populations. Thus, we must emphasize that the wild-type allele, *1, is scored by default, and hence may actually be overrepresented in the survey. Another limitation is that the assay for DNA typing the CYP2D6 gene does not identify directly which allele is duplicated. While alleles *1 and *2, if duplicated, may be associated with supra-functional status, null allele *4 certainly may not. Nevertheless, we believe this study documents the prevalence of the most commonly observed deficient and null alleles for each of the three CYP2 genes surveyed, which are of immediate clinical relevance. We are also pursuing DNA typing of CYP genes is of immediate clinical relevance [13, 14] . Foremost, carriers of two null alleles for a given CYP gene cannot metabolize drugs requiring the specific enzyme coded by that gene. The use of such drugs should be contraindicated in these patients given their inability to metabolize the drug that could result in elevated serum levels and toxicity. The observation of a prevalence of 6% for carriers of two null alleles for CYP2D6 in the population has substantial implications for psychiatry [15, 16] . Many antidepressants (paroxetine and venlaxafine) and stimulants (atomoxetine and dextroamphetamine) are metabolized by the isoenzyme encoded by this gene. Prescribing these drugs to a null metabolizer could result in problematic side effects including agitation and suicidal ideation. Similarly, the observation of a prevalence of 3% for double carriers of CYP2C9 deficient alleles has implications for cardiovascular medicine. Warfarin, widely used for the prevention of thromboembolism, is metabolized by the isoenzyme encoded by this gene. Bleeding complications could result in individuals highly compromised in CYP2C9 enzymatic activity [17, 18] . Uninformed prescribing of antidepressants or warfarin to individuals with highly compromised biochemical activity for the respective drug-metabolizing isoenzyme, may expose one of every 20 patients to preventable severe side effects. DNA typing can be relevant to other drugs with a narrow therapeutic index, in order to enhance patient safety and improve outcome. However, a deficiency in innate metabolic capacity revealed by DNA typing should not be considered a disease, but a risk factor for ADRs.
Recent policies at the US FDA incorporate DNA typing information for safe and effective drug prescribing [19] . The label for atomoxetine, a stimulant used in attention deficit hyperactivity disorder (ADHD), warns that poor metabolizers have plasma levels that are five times elevated with regard to extensive metabolizers, and states "laboratory tests are available to identify CYP2D6 poor metabolizers". It is expected that the label for warfarin may be revised with pharmacogenetic information with regard to CYP2C9 metabolizer status according to recent deliberations of the US FDA's Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science [102] .
The practice of personalized medicine will be increasingly dependent on defining innate drug metabolizing capacity by DNA typing and managing therapy on an individualized basis [20] . This study incorporating parallel DNA typing of three CYP2 genes, to be supplemented in the near future with surveys of variability in the CYP1 and CYP3 gene families, constitutes a novel strategy for creating overall measures of drug metabolism capacity based on multigene allelic arrays. We foresee immediate application of DNA typing in the diagnosis of ADRs and prevention of drug side effects in general. 
